Which vein is safer for chemotherapy ports? a trial aims to settle the debate

NCT ID NCT03945045

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial compares two common methods for placing a totally implantable vascular access device (TIVAD), a port used for chemotherapy and other treatments in cancer patients. Researchers are randomly assigning patients to have the port inserted via either the internal jugular vein (neck) or the subclavian vein (chest). The goal is to see which approach leads to fewer complications, such as blood clots, infections, or device malfunctions, over two years of follow-up.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a procedure comparing two vein approaches (internal jugular vein vs. subclavian vein) for implanting a totally implantable vascular access device (TIVAD)
What this could lead to
If one approach proves safer, it could become the standard method for placing long-term central lines in cancer patients, reducing complications like blood clots and infections.
What could go wrong
This is a single-center trial with 240 patients, so results may not apply to all settings. The study focuses on short-term complications and does not address long-term device performance beyond two years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer Catheter-Related Infections thrombophilia due to thrombin defect Venous Thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Taiwan University Hospital

    Taipei, Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.